Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years' follow-up.

European journal of neurology - 1 Dec 2021

Sánchez-Rodríguez Antonio, Martínez-Rodríguez Isabel, Sánchez-Juan Pascual, Sierra María, González-Aramburu Isabel, Rivera-Sánchez María, Andrés-Pacheco Javier, Gutierrez-González Ángela, García-Hernández Adrián, Madera Jorge, Delgado-Alvarado Manuel, Infante Jon

Abstract excerpt

BACKGROUND: Carriers of the G2019S mutation of LRRK2 provide a great opportunity to investigate the premotor stages of Parkinson's disease (PD). We have studied by serial clinical and dopamine transporter single photon emission computed tomography (DaT-SPECT) evaluations a cohort of asymptomatic carriers of the LRRK2-G2019S mutation in order to evaluate the usefulness of these tools as biomarkers. Here we report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Dopamine Plasma Membrane Transport Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Mutation

Share to Tomography, Emission-Computed, Single-Photon

Source

Identifiers

PMID: 34407293
DOI: 10.1111/ene.15070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years' follow-up.PMID 34407293Read ↗

Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.Semantic proximity Read ↗

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.Semantic proximity Read ↗

The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.Semantic proximity Read ↗

DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.Semantic proximity Read ↗

Dopamine D2 receptor upregulation in dorsal striatum in the <i>LRRK2</i> -R1441C rat model of early Parkinson’s disease revealed by <i>in vivo</i> PET imagingSemantic proximity Read ↗

Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.Semantic proximity Read ↗

Progression in the LRRK2-Asssociated Parkinson Disease Population.Semantic proximity Read ↗

Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET NeuroimagingSemantic proximity Read ↗

Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-Synuclein Seeding ActivitySemantic proximity Read ↗

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.Semantic proximity Read ↗

Nigrostriatal dysfunction in homozygous and heterozygous <i>parkin</i> gene carriers: An <sup>18</sup>F‐dopa PET progression studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.